Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Eureka Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Porton Advanced, Eureka Collaborate to Accelerate T-Cell Therapy
Details : The collaboration aims to leverage proprietary ARTEMIS cell receptor and E‑ALPHA antibody discovery platforms to drive innovation in safer, more effective T‑cell therapies.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 19, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Eureka Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Ligachem Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
WuXi XDC & LigaChem Expand MOU to Boost ADC Development
Details : Through the collaboration, WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
February 25, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Ligachem Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Adcendo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Duality Biologics Expands Adcendo Collaboration via Strategic License Agreement
Details : Adcendo exercises its option to utilize Duality's platform to further enhance its first-in-class ADC pipeline and develop highly differentiated novel ADCs for the treatment of hard-to-treat cancers.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Adcendo
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Agreement
WuXi Biologics Partners with BioNTech for Monoclonal Antibodies Discovery
Details : Under the agreement, WuXi Biologics will use its antibody discovery tech to find two undisclosed preclinical targets for BioNTech's next-gen therapeutic product candidates.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $20.0 million
November 01, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : BioNTech
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Bridge Biotherapeutics and HitGen Collaborate on Novel Cancer Therapeutics Program
Details : The collaboration builds on successful initial hit finding and identification work from HitGen's DNA-encoded library, aiming to further develop the novel hits as promising drug candidates for cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Bridge Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : WeComput
Deal Size : Undisclosed
Deal Type : Partnership
Innovent and WeComput Announce Partnership to Advance AI-Driven Drug Discovery
Details : Innovent and WeMol will integrate their technological strengths to create a comprehensive AI-driven drug discovery and development for the treatment of neoplasms, and cardiovascular diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : WeComput
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : BioCopy AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocytogen Enters Evaluation Agreement with BioCopy for TCR-Mimic Antibodies
Details : BioCopy has gained access to TCR-mimic antibodies targeting intracellular antigens developed by Biocytogen’s proprietary RenTCR-mimic mice, to evaluate these antibodies for novel cancer therapies.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : BioCopy AG
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Multitude Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
WuXi XDC Partners with Multitude and HySlink for ADC Discovery Technology
Details : Multitude Therapeutics will provide T-Moiety linker technologies to accelerate discovery of preclinical ADC candidates and develop novel bioconjugates for cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Multitude Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Ona Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Biocytogen will grant Ona access to evaluate Biocytogen’s proprietary RenMice®-derived fully human antibodies against a specific tumor target, with an option to exclusively license selected antibodies for ADC development, manufacturing and commerciali...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Ona Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Myricx Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Myricx Enters into Antibody License Agreement with Biocytogen
Details : Under the terms of the agreement, Myricx will develop and commercialize ADCs based on an antibody developed using Biocytogen’s proprietary RenMice® platform and will expand Myricx’s ADC pipeline of proprietary monoclonal antibodies (mAbs) against im...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Myricx Bio
Deal Size : Undisclosed
Deal Type : Licensing Agreement